Nancy T. Chang
Chang Tang Chang | |
|---|---|
| 唐南珊 | |
Chang in 2012 | |
| Born | 1950 (age 75–76) |
| Education | National Tsing Hua University (BS) Brown University (BA) Harvard University (PhD) |
| Known for | Xolair |
| Awards | Biotechnology Heritage Award |
| Scientific career | |
| Fields | Biological chemistry |
| Workplaces | Tanox |
| Thesis | Comparative studies of the fibroin gene of various silk worm species (1981) |
Chang Tang Chang (née Tang Nanshan; Chinese: 唐南珊; pinyin: Táng Nánshān; born 1950), also known by her English name Nancy Chang, is a Taiwanese biochemist. She co-founded the biopharmaceutical company Tanox in 1986. She also developed the asthma drug Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million.